Immunosuppression for liver transplantation

Gut

Volumn 58, Issue 3, 2009, Pages 452-463

  Geissler, E K ^a,b   Schlitt, H J ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

4 [N [1 (2 CYANO 1 OXOETHYL) 4 METHYL 3 PIPERIDINYL] N METHYLAMINO]PYRROLO[2,3 D]PYRIMIDINE; ALEMTUZUMAB; ARACHIDONIC ACID; AZATHIOPRINE; B7 ANTIGEN; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CD86 ANTIGEN; CORTICOSTEROID; CYCLOPHILIN; CYCLOSPORIN; DACLIZUMAB; EFALIZUMAB; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2 RECEPTOR ANTIBODY; MAJOR HISTOCOMPATIBILITY ANTIGEN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; SOTRASTAURIN; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; TRANSCRIPTION FACTOR NFAT; TRANSFORMING GROWTH FACTOR BETA; UNINDEXED DRUG;

ALLOGRAFT; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ANTIVIRAL ACTIVITY; ARACHIDONIC ACID METABOLISM; B LYMPHOCYTE; BLOOD SAMPLING; CANCER RECURRENCE; CELL PROLIFERATION; CELL THERAPY; CLINICAL EVALUATION; CLINICAL TRIAL; DENDRITIC CELL; DIABETES MELLITUS; DRUG ABSORPTION; DRUG BINDING; DRUG BLOOD LEVEL; DRUG COST; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG TOLERABILITY; ENTERIC COATED TABLET; FIBROSIS; GASTROINTESTINAL SYMPTOM; GENETIC TRANSCRIPTION; GRAFT RECIPIENT; GRAFT SURVIVAL; HEMATOPOIETIC CELL; HEPATITIS; HEPATITIS C; HEPATITIS C VIRUS REINFECTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; IMMUNOLOGICAL TOLERANCE; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY TRANSPLANTATION; KUPFFER CELL; LEG EDEMA; LIVER CELL CARCINOMA; LIVER FAILURE; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; LYMPHOCYTE DEPLETION; LYMPHOPROLIFERATIVE DISEASE; MACROPHAGE; MEMORY T LYMPHOCYTE; MICROCHIMERISM; MONOCYTE; MONOTHERAPY; MOUTH ULCER; NATURAL KILLER CELL; NEPHROTOXICITY; OBESITY; OSTEOPOROSIS; PRIORITY JOURNAL; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; REINFECTION; REPERFUSION INJURY; REVIEW; RISK REDUCTION; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TARGET CELL; THYMOCYTE; TUMOR GROWTH; VIRUS LOAD; VIRUS REPLICATION; WOUND HEALING;

ANTILYMPHOCYTE SERUM; CALCINEURIN; FEMALE; HOST VS GRAFT REACTION; HUMANS; IMMUNITY, CELLULAR; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; TISSUE AND ORGAN PROCUREMENT;

EID: 61649104846     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gut.2008.163527     Document Type: Review

References (105)

1. Rasmussen A, Davies HF, Jamieson NV, et al. Combined transplantation of liver and kidney from the same donor protects the kidney from rejection and improves kidney graft survival. Transplantation 1995;59:919-21.
2. Kotru A, Sheperd R, Nadler M, et al. Combined lung and liver transplantation: the United States experience. Transplantation 2006;82:144-5.
3. Kamada N, Davies HS, Roser B. Reversal of transplantation immunity by liver grafting. Nature 1981;292:840-3.
4. Navarro V, Herrine S, Katopes C, et al. The effect of HLA class I (A and B) and class II (DR) compatibility on liver transplantation outcomes: an analysis of the OPTN database. Liver Transpl 2006;12:652-8.
5. Sieders E, Hepkema BG, Peeters PM, et al. The effect of HLA mismatches, shared cross-reactive antigen groups, and shared HLA-DR antigens on the outcome after pediatric liver transplantation. Liver Transpl 2005;11:1541-9.
6. Fung JJ, Makowka L, Griffin M, et al. Successful sequential liver-kidney transplantation in patients with performed lymphocytotoxic antibodies. Clin Transplant 1987;1:187-94.
7. Calne RY, Sells RA, Pena JR, et al. Induction of immunological tolerance by porcine liver allografts. Nature 1969;223:472-6.
8. Tisone G, Orlando G, Angelico M. Operational tolerance in clinical liver transplantation: emerging developments. Transpl Immunol 2007;17:108-13.
9. Billingham RE, Brent L, Medawar PB. Actively acquired tolerance of foreign cells. Nature 1953;172:603-6.
10. Scandling JD, Busque S, Dejbakhsh-Jones S, et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008;358:362-8.
11. Alexander SI, Smith N, Hu M, et al. Chimerism and tolerance in a recipient of a deceased-donor liver transplant. N Engl J Med 2008;358:369-74.
12. Kawai T, Cosimi AB, Spitzer TR, et al. HLA-mismatched renal transplantation without maintenance immunosuppression. N Engl J Med 2008;358:353-61.
13. Rodriguez-Luna H, Douglas DD. Natural history of hepatitis C following liver transplantation. Curr Opin Infect Dis 2004;17:363-71.
14. Gautam M, Cheruvattath R, Balan V. Recurrence of autoimmune liver disease after liver transplantation: a systematic review. Liver Transpl 2006;12:1813-24.
15. Mannon RB. Therapeutic management of posttransplant diabetes mellitus. Transplant Rev 2008;22:116-24.
16. Xu X, Ling Q, He ZL, et al. Post-transplant diabetes mellitus in liver transplantation: Hangzhou experience. Hepatobiliary Pancreat Dis Int 2008;7:465-70.
17. Borel JF, Feurer C, Gubler HU, et al. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976;6:468-75.
18. Calne RY, White DJ, Thiru S, et al. Cyclosporin A in patients receiving renal allografts from cadaver donors. Lancet 1978;2:1323-7.
19. Hutchinson IV. The mode of action of Prograf (tacrolimus) and its significance for long-term graft survival. New Horizons Kidney Transplantation 1997 1997;1:22-6.
20. 0 monitoring in de novo liver transplantation. Transplantation 2004;77:1632-8.
21. Ojo AO, Held PJ, Port FK, et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003;349:931-40.
22. Schiff J, Cole E, Cantarovich M. Therapeutic monitoring of calcineurin inhibitors for the nephrologist. Clin J Am Soc Nephrol 2007;2:374-84.
23. Firpi RJ, Zhu H, Morelli G, et al. Cyclosporine suppresses hepatitis C virus in vitro and increases the chance of a sustained virological response after liver transplantation. Liver Transpl 2006;12:51-7.
24. Henry SD, Metselaar HJ, Lonsdale RC, et al. Mycophenolic acid inhibits hepatitis C virus replication and acts in synergy with cyclosporin A and interferon-alpha. Gastroenterology 2006;131:1452-62.
25. Watashi K, Hijikata M, Hosaka M, et al. Cyclosporin A suppresses replication of hepatitis C virus genome in cultured hepatocytes. Hepatology 2003;38:1282-8.
26. Berenguer M, Royuela A, Zamora J. Immunosuppression with calcineurin inhibitors with respect to the outcome of HCV recurrence after liver transplantation: results of a meta-analysis. Liver Transpl 2007;13:21-9.
27. Hojo M, Morimoto T, Maluccio M, et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 1999;397:530-4.
28. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002;8:128-35.
29. Koehl G, Andrassy J, Guba M, et al. Rapamycin protects allografts from rejection while simultaneously attacking tumors in immunosuppressed mice. Transplantation 2004;77:1319-26.
30. Gosio B. Sperimentate su culture pure di bacilli del carbonchio demonstrarano notevole potere antisettica. C R Acad Med Torino 1893;61:484.
31. Franklin TJ, Cook JM. The inhibition of nucleic acid synthesis by mycophenolic acid. Biochem J 1969;113:515-24.
32. Sollinger HW. Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. U.S. Renal Transplant Mycophenolate Mofetil Study Group. Transplantation 1995;60:225- 32.
33. Pescovitz MD, Conti D, Dunn J, et al. Intravenous mycophenolate mofetil: safety, tolerability, and pharmacokinetics. Clin Transplant 2000;14:179-88.
34. Schmidt H, Brockmann J. MMF to EC-MPS conversion: what makes the difference? Liver Transpl 2007;13:773-4.
35. Schlitt HJ, Barkmann A, Böker KHW, et al. Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study. Lancet 2001;357:587-91.
36. Stewart SF, Hudson M, Talbot D, et al. Mycophenolate mofetil monotherapy in liver transplantation. Lancet 2001;357:609- 10.
37. Fisher RA, Ham JM, Marcos A, et al. A prospective randomized trial of mycophenolate mofetil with neoral or tacrolimus after orthotopic liver transplantation. Transplantation 1998;66:1616-21.
38. Barkmann A, Nashan B, Schmidt HH, et al. Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil. Transplantation 2000;69:1886-90.
39. Hao C, Anwei M, Bing C, et al. Monitoring mycophenolic acid pharmacokinetic parameters in liver transplant recipients: prediction of occurrence of leukopenia. Liver Transpl 2008;14:1165-73.
40. Hao C, Erzheng C, Anwei M, et al. Validation of limited sampling strategy for the estimation of mycophenolic acid exposure in Chinese adult liver transplant recipients. Liver Transpl 2007;13:1684-93.
41. Stangl JR, Carroll KL, Illichmann M, et al. Effect of antimetabolite immunosuppressants on Flaviviridae, including hepatitis C virus. Transplantation 2004;77:562-7.
42. Nebbia G, Mattes FM, Sabin CA, et al. Differential effects of prednisolone and azathioprine on the development of human cytomegalovirus replication post liver transplantation. Transplantation 2007;84:605-10.
43. Zekry A, Gleeson M, Guney S, et al. A prospective cross-over study comparing the effect of mycophenolate versus azathioprine on allograft function and viral load in liver transplant recipients with recurrent chronic HCV infection. Liver Transpl 2004;10:52-7.
44. Sehgal SN. Sirolimus: its discovery, biological properties, and mechanism of action. Transplant Proc 2003;35:7S-14S.
45. Fairbanks KD, Eustace JA, Fine D, et al. Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus. Liver Transplantation 2003;9:1079-85.
46. Diekmann F, Gutierrez-Dalmau A, Lopez S, et al. Influence of sirolimus on proteinuria in de novo kidney transplantation with expanded criteria donors: comparison of two CNI-free protocols. Nephrol Dial Transpl 2007;22:2316-21.
47. Bumbea V, Kamar N, Ribes D, et al. Long-term results in renal transplant patients with allograft dysfunction after switching from calcineurin inhibitors to sirolimus. Nephrol Dial Transplant 2005;20:2517-23.
48. Letavernier E, Pe'raldi MN, Pariente A, et al. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005;80:1198-203.
49. Kneteman NM, Oberholzer J, Al Saghier M, et al. Sirolimus-based immunosuppression for liver transplantation in the presence of extended criteria for hepatocellular carcinoma. Liver Transplantation 2004;10:1301-11.
50. Dunkelberg JC, Trotter JF, Wachs M, et al. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl 2003;9:463-8.
51. Li Y, Li XC, Zheng XX, et al. Blocking both signal 1 and signal 2 of T-cell activation prevents apoptosis of alloreactive T cells and induction of peripheral allograft tolerance. Nat Med 1999;5:1298- 302.
52. Li Y, Zheng XX, Li XC, et al. Combined costimulation blockade plus rapamycin but not cyclosporine produces permanent engraftment. Transplantation 1998;66:1387-8.
53. + T cells. Blood 2008;111:453-62.
54. Sauer S, Bruno L, Hertweck A, et al. T cell receptor signaling controls Foxp3 expression via PI3K, Akt, and mTOR. Proc Natl Acad Sci U S A 2008;105:7797-802.
55. + cells. J Exp Med 2008;205:565-74.
56. Schiopu A, Wood KJ. Regulatory T cells: hypes and limitations. Curr Opin Organ Transplant 2008;13:333-8.
57. Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002;73:1565-72.
58. Guertin DA, Sabatini DM. Defining the role of mTOR in cancer. Cancer Cell 2007;12:9-22.
59. Zhou J, Wulfkuhle J, Zhang H, et al. Activation of the PTEN/ mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci U S A 2007;104: 16158-63.
60. Hudes G, Carducci M, Tomczak P, et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med 2007;356:2271-81.
61. Motzer RJ, Escudier B, Oudard S, et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled phase III trial. Lancet 2008;372:449-56.
62. Toso C, Meeberg GA, Bigam DL, et al. De novo sirolimus-based immunosuppression after liver transplantation for hepatocellular carcinoma: long-term outcomes and side effects. Transplantation 2007;83:1162-8.
63. Neef M, Ledermann M, Saegesser H, et al. Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. J Hepatol 2006;45:786-96.
64. Henry SD, Metselaar HJ, Van Dijck J, et al. Impact of steroids on hepatitis C virus replication in vivo and in vitro. Ann N Y Acad Sci 2007;1110:439-47.
65. Vivarelli M, Burra P, La Barba G, et al. Influence of steroids on HCV recurrence after liver transplantation: A prospective study. J Hepatol 2007;47:793-8.
66. Segev DL, Sozio SM, Shin EJ, et al. Steroid avoidance in liver transplantation: meta-analysis and meta-regression of randomized trials. Liver Transpl 2008;14:512-25.
67. Soliman T, Hetz H, Burghuber C, et al. Short-term induction therapy with anti-thymocyte globulin and delayed use of calcineurin inhibitors in orthotopic liver transplantation. Liver Transpl 2007;13:1039- 44.
68. Lundquist AL, Chari RS, Wood JH, et al. Serum sickness following rabbit antithymocyte-globulin induction in a liver transplant recipient: case report and literature review. Liver Transpl 2007;13:647-50.
69. + regulatory T cells in vitro. Blood 2008;111:3675-83.
70. + regulatory T cells. J Am Soc Nephrol 2006;17:2844-53.
71. Lytton SD, Denton CP, Nutzenberger AM. Treatment of autoimmune disease with rabbit anti-T lymphocyte globulin: clinical efficacy and potential mechanisms of action. Ann N Y Acad Sci 2007;1110:285-96.
72. Neuhaus P, Clavien PA, Kittur D, et al. Improved treatment response with basiliximab immunoprophylaxis after liver transplantation: results from a double-blind randomized placebo-controlled trial. Liver Transpl 2002;8:132-42.
73. Liu CL, Fan ST, Lo CM, et al. Interleukin-2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: a protocol with early elimination of steroids and reduction of tacrolimus dosage. Liver Transpl 2004;10:728-33.
74. Ramirez CB, Doria C, Di Francesco F, et al. Anti-IL2 induction in liver transplantation with 93% rejection-free patient and graft survival at 18 months. J Surg Res 2007;138:198-204.
75. Hirose R, Roberts JP, Quan D, et al. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation 2000;69:307-11.
76. Calmus Y, Scheele JR, Gonzalez-Pinto I, et al. Immunoprophylaxis with basiliximab, a chimeric anti-interleukin-2 receptor monoclonal antibody, in combination with azathioprine-containing triple therapy in liver transplant recipients. Liver Transpl 2002;8:123-31.
77. + regulatory T cells detach from the graft and circulate in recipients after liver transplantation. J Immunol 2007;178:6066-72.
78. + regulatory T cells. Am J Transplant 2008;8:1639-51.
79. Li W, Carper K, Liang Y, et al. Anti-CD25 mAB administration prevents spontaneous liver transplant tolerance. Transplant Proc 2006;38:3207-8.
80. Waldmann H, Polliak A, Hale G, et al. Elimination of graft-versus-host disease by in-vitro depletion of alloreactive lymphocytes with a monoclonal rat anti-human lymphocyte antibody (CAMPATH-1). Lancet 1984;2:483-6.
81. Magliocca JF, Knechtle SJ. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transpl Int 2006;19:705-14.
82. Watson CJ, Bradley JA, Friend PJ, et al. Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation - efficacy and safety at five years. Am J Transplant 2005;5:1347-53.
83. Pascual J, Bloom D, Torrealba J, et al. Calcineurin inhibitor withdrawal after renal transplantation with alemtuzumab: clinical outcomes and effect on T-regulatory cells. Am J Transplant 2008;8:1529-36.
84. Barth RN, Janus CA, Lillesand CA, et al. Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transpl Int 2006;19:885-92.
85. + regulatory T cells increase de novo in kidney transplant patients after immunodepletion with Campath-1H. Am J Transplant 2008;8:793-802.
86. Tzakis AG, Tryphonopoulos P, Kato T, et al. Preliminary experience with alemtuzumab (Campath-1H) and low-dose tacrolimus immunosuppression in adult liver transplantation. Transplantation 2004;77:1209-14.
87. Marcos A, Eghtesad B, Fung JJ, et al. Use of alemtuzumab and tacrolimus monotherapy for cadaveric liver transplantation: with particular reference to hepatitis C virus. Transplantation 2004;78:966-71.
88. Tryphonopoulos P, Weppler D, Nishida S, et al. Six year experience with Campath-1H (C1H) induction in adult liver transplantation. Am J Transplant 2008;8(suppl 2):307.
89. Vincenti F, Larsen C, Durrbach A, et al. Costimulation blockade with belatacept in renal transplantation. New EnglJ Med 2005;353:770-81.
90. Pribila JT, Quale AC, Mueller KL, et al. Integrins and T cell-mediated immunity. Annu Rev Immunol 2004;22:157-80.
91. Metzler B, Gfeller P, Bigaud M, et al. Combinations of anti-LFA-1, everolimus, anti-CD40 ligand, and allogeneic bone marrow induce central transplantation tolerance through hemopoietic chimerism, including protection from chronic heart allograft rejection. J Immunol 2004;173:7025-36.
92. Rayat GR, Gill RG. Indefinite survival of neonatal porcine islet xenografts by simultaneous targeting of LFA-1 and CD154 or CD45RB. Diabetes 2005;54:443-51.
93. Vincenti F, Mendez R, Pescovitz M, et al. A phase I/II randomized open-label multicenter trial of efalizumab, a humanized anti-CD11a, anti-LFA-1 in renal transplantation. Am J Transplant 2007;7:1770- 7.
94. McCurry KR, Colvin BL, Zahorchak AF, et al. Regulatory dendritic cell therapy in organ transplantation. Transpl Int 2006;19:525-38.
95. Brem-Exner BG, Sattler C, Hutchinson JA, et al. Macrophages driven to a novel state of activation have anti-inflammatory properties in mice. J Immunol 2008;180:335-49.
96. Hoffmann P, Eder R, Boeld TJ, et al. Only the CD45RA+ subpopulation of CD4+CD25high T cells gives rise to homogeneous regulatory T-cell lines upon in vitro expansion. Blood 2006;108:4260-7.
97. Hutchinson JA, Riquelme P, Brem-Exner BG, et al. Transplant acceptance-inducing cells as an immune-conditioning therapy in renal transplantation. Transpl Int 2008;21:728-41.
98. Hutchinson JA, Brem-Exner BG, Riquelme P, et al. A cell-based approach to the minimization of immunosuppression in renal transplantation. Transpl Int 2008;21:742-54.
99. Hutchinson JA, Roelen D, Riquelme P, et al. Preoperative treatment of a presensitized kidney transplant recipient with donor-derived transplant acceptance-inducing cells. Transpl Int 2008;21:808-13.
100. Mazariegos GV, Reyes J, Marino IR, et al. Weaning of immunosuppression in liver transplant recipients. Transplantation 1997;63:243-9.
101. Girlanda R, Rela M, Williams R, et al. Long-term outcome of immunosuppression withdrawal after liver transplantation. Transplant Proc 2005;37:1708-9.
102. Takatsuki M, Uemoto S, Inomata Y, et al. Weaning of immunosuppression in living donor liver transplant recipients. Transplantation 2001;72:449-54.
103. Li Y, Koshiba T, Yoshizawa A, et al. Analyses of peripheral blood mononuclear cells in operational tolerance after pediatric living donor liver transplantation. Am J Transplant 2004;4:2118-25.
104. Eason JD, Cohen AJ, Nair S, et al. Tolerance: is it worth the risk? Transplantation 2005;79:1157-9.
105. Martinez-Llordella M, Lozano JJ, Puig-Pey I, et al. Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. J Clin Invest 2008;118:2845-57.